Stock Track | GoodRx Stock Soars 5.5% Pre-Market on Upbeat 2025 Outlook Despite Q4 Miss

Stock Track

02-27

Shares of GoodRx Holdings Inc. (GDRX) surged 5.52% in pre-market trading on Thursday, following the prescription savings platform company's mixed fourth quarter 2024 results but upbeat outlook for 2025.

For the fourth quarter, GoodRx reported adjusted earnings per share of $0.09, matching analyst estimates. However, revenue of $198.6 million came in slightly below the $199.8 million expected by Wall Street. Despite the Q4 revenue miss, investors appeared encouraged by the company's guidance for continued growth momentum in 2025.

For the full year 2025, GoodRx forecast revenue in the range of $810 million to $840 million, representing year-over-year growth of 2% to 6%. The company also expects adjusted EBITDA of $270 million to $286 million, up 4% to 10% from 2024 levels. Management cited expanding relationships across the pharmacy ecosystem and plans to broaden the company's solution set as key drivers of the positive 2025 outlook.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1182259989"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182259989\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1182259989?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182259989","market":"us","top_or_hot":-1,"title":"Stock Track | GoodRx Stock Soars 5.5% Pre-Market on Upbeat 2025 Outlook Despite Q4 Miss","media":"Stock Track","content":"<p>Shares of GoodRx Holdings Inc. (GDRX) surged 5.52% in pre-market trading on Thursday, following the prescription savings platform company's mixed fourth quarter 2024 results but upbeat outlook for 2025.</p>\n\n<p>For the fourth quarter, GoodRx reported adjusted earnings per share of $0.09, matching analyst estimates. However, revenue of $198.6 million came in slightly below the $199.8 million expected by Wall Street. Despite the Q4 revenue miss, investors appeared encouraged by the company's guidance for continued growth momentum in 2025.</p>\n\n<p>For the full year 2025, GoodRx forecast revenue in the range of $810 million to $840 million, representing year-over-year growth of 2% to 6%. The company also expects adjusted EBITDA of $270 million to $286 million, up 4% to 10% from 2024 levels. Management cited expanding relationships across the pharmacy ecosystem and plans to broaden the company's solution set as key drivers of the positive 2025 outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GoodRx Stock Soars 5.5% Pre-Market on Upbeat 2025 Outlook Despite Q4 Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GoodRx Stock Soars 5.5% Pre-Market on Upbeat 2025 Outlook Despite Q4 Miss\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-27 22:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of GoodRx Holdings Inc. (GDRX) surged 5.52% in pre-market trading on Thursday, following the prescription savings platform company's mixed fourth quarter 2024 results but upbeat outlook for 2025.</p>\n\n<p>For the fourth quarter, GoodRx reported adjusted earnings per share of $0.09, matching analyst estimates. However, revenue of $198.6 million came in slightly below the $199.8 million expected by Wall Street. Despite the Q4 revenue miss, investors appeared encouraged by the company's guidance for continued growth momentum in 2025.</p>\n\n<p>For the full year 2025, GoodRx forecast revenue in the range of $810 million to $840 million, representing year-over-year growth of 2% to 6%. The company also expects adjusted EBITDA of $270 million to $286 million, up 4% to 10% from 2024 levels. Management cited expanding relationships across the pharmacy ecosystem and plans to broaden the company's solution set as key drivers of the positive 2025 outlook.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GDRX","symbol_name":"GoodRx Holdings, Inc.","start_time":0,"source_url":"","article_id":"1182259989","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182259989","pubTimestamp":1740667601,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of GoodRx Holdings Inc.  surged 5.52% in pre-market trading on Thursday, following the prescription savings platform company's mixed fourth quarter 2024 results but upbeat outlook for 2025.For the fourth quarter, GoodRx reported adjusted earnings per share of $0.09, matching analyst estimates. However, revenue of $198.6 million came in slightly below the $199.8 million expected by Wall Street. Despite the Q4 revenue miss, investors appeared encouraged by the company's guidance for continu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GDRX":"GoodRx Holdings, Inc."},"translate_title":"尽管第四季度业绩不佳，但由于2025年前景乐观，GoodRx股价盘前飙升5.5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GDRX":1},"content_text":"Shares of GoodRx Holdings Inc. (GDRX) surged 5.52% in pre-market trading on Thursday, following the prescription savings platform company's mixed fourth quarter 2024 results but upbeat outlook for 2025.\nFor the fourth quarter, GoodRx reported adjusted earnings per share of $0.09, matching analyst estimates. However, revenue of $198.6 million came in slightly below the $199.8 million expected by Wall Street. Despite the Q4 revenue miss, investors appeared encouraged by the company's guidance for continued growth momentum in 2025.\nFor the full year 2025, GoodRx forecast revenue in the range of $810 million to $840 million, representing year-over-year growth of 2% to 6%. The company also expects adjusted EBITDA of $270 million to $286 million, up 4% to 10% from 2024 levels. Management cited expanding relationships across the pharmacy ecosystem and plans to broaden the company's solution set as key drivers of the positive 2025 outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}